NuVasive, Inc. (NUVA)
(Delayed Data from NSDQ)
$62.96 USD
+0.74 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $62.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$62.96 USD
+0.74 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $62.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Smith & Nephew's Study Outcomes for REGENETEN Encouraging
by Zacks Equity Research
Smith & Nephew's (SNN) announces positive study outcomes for REGENETEN.
Pacific Biosciences (PACB) Q3 Loss Wider Than Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) gains from solid segmental contributions in the third quarter.
Zimmer (ZBH) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Zimmer (ZBH) is optimistic about maintaining its growth momentum on several recent positive developments.
Medtronic (MDT) Beats on Q2 Earnings, Ups FY20 EPS Guidance
by Zacks Equity Research
Medtronic (MDT) demonstrates improved performances at CER, banking on growth in all major business segments and geographies.
Edwards Lifesciences (EW) Recalls PASCAL's Guide Sheath
by Zacks Equity Research
Edwards Lifesciences (EW) issues a product recall for its guide sheath based on report from its urgent field safety notice.
QIAGEN Rides on Solid QuantiFERON-TB Sales Amid Several Woes
by Zacks Equity Research
QIAGEN (QGEN) pins hopes on its key strategic collaborations with Hamilton Robotics and Tecan for the pre-analytical handling of blood tubes.
Amedisys Partners With nVoq to Improve Clinician Experience
by Zacks Equity Research
Amedisys (AMED) aims to enhance clinician workflow by integrating nVoq's technology platform into its home health business.
Canopy Growth (CGC) Q2 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Canopy Growth (CGC) reports mixed fiscal second-quarter results on strength in its core segments.
Haemonetics (HAE) Grows on New Products, Robust Plasma Sales
by Zacks Equity Research
Haemonetics (HAE) witnesses a steady uptick in Plasma franchise, fueled by favorable price, volume and mix.
Insulet (PODD) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Insulet (PODD) has been gaining from several positive developments recently.
Here's Why You Should Hold on to CVS Health (CVS) For Now
by Zacks Equity Research
Investors can still hold on to CVS Health (CVS) stock, thanks to its solid prospects.
CVS Health's New Plans With Aetna May Improve Health Outcomes
by Zacks Equity Research
CVS Health's (CVS) Health Care Benefits segment develops Medicare program with Aetna.
Syneos Health Collaborates with AiCure for Patient Engagement
by Zacks Equity Research
Syneos Health (SYNH) aims to optimize patient engagement and trial success by partnering with AiCure.
Here's Why You Should Add NuVasive (NUVA) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about NuVasive's (NUVA) stellar performance.
Insulet Rides on Omnipod's Wider Market Reach, New Products
by Zacks Equity Research
Insulet (PODD) achieves several milestones with respect to strengthening Omnipod's market access.
Hologic's (HOLX) 3DQuorum Imaging Technology Gets FDA Nod
by Zacks Equity Research
The regulatory clearance is likely to boost Hologic's (HOLX) Breast and Skeletal Health Solutions business segment.
Globus Medical's U.S. Spine Arm Grows, Product Launches Aid
by Zacks Equity Research
Globus Medical (GMED) is on course to commercially market ExcelsiusGPS platform and launch its spine deformity solution in early fourth quarter.
Hologic's Aptima Genitalium Assay Gets Clinically Verified
by Zacks Equity Research
This study result is expected to be a major stride forward in Hologic's (HOLX) commitment toward strengthening its Diagnostic Solutions business.
Medtronic (MDT) Releases Positive Study Results on Pacemaker
by Zacks Equity Research
Medtronic (MDT) presents favorable results from study on leadless pacemaker, indicating potential for improving cardiac functions in patients having blockages.
CVS Health's Aetna Prospects Solid, Omnicare Sluggish
by Zacks Equity Research
CVS Health's (CVS) strong Pharmacy Services segment sales gain traction from growth in specialty services.
Zimmer (ZBH) Scales 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Zimmer (ZBH) is likely to maintain the current high on a number of favorable factors.
Myriad Genetics Presents New Test Data in Autoimmune Segment
by Zacks Equity Research
Myriad Genetics (MYGN) presents key findings related to Vectra test from its autoimmune segment.
National Vision's (EYE) Q3 Earnings Top Estimates, View Raised
by Zacks Equity Research
National Vision's (EYE) third-quarter performance reflects strong growth in core business segments.
Globus Medical (GMED) Q3 Earnings Meet Mark, Revenue View Up
by Zacks Equity Research
Globus Medical (GMED) reports robust top-line numbers for the third quarter on segmental strength.
Hologic's (HOLX) Q4 Earnings Meet, Revenues Top Estimates
by Zacks Equity Research
Hologic (HOLX) exhibits robust fourth-quarter growth fueled by strong segmental performance.